LMAT vs. MDXG, CSII, CRY, SIBN, OFIX, PEN, GKOS, MMSI, HAE, and INSP
Should you be buying LeMaitre Vascular stock or one of its competitors? The main competitors of LeMaitre Vascular include MiMedx Group (MDXG), Cardiovascular Systems (CSII), CryoLife (CRY), SI-BONE (SIBN), Orthofix Medical (OFIX), Penumbra (PEN), Glaukos (GKOS), Merit Medical Systems (MMSI), Haemonetics (HAE), and Inspire Medical Systems (INSP). These companies are all part of the "medical" sector.
MiMedx Group (NASDAQ:MDXG) and LeMaitre Vascular (NASDAQ:LMAT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, media sentiment, valuation, earnings, community ranking, analyst recommendations, profitability and dividends.
79.2% of MiMedx Group shares are held by institutional investors. Comparatively, 84.6% of LeMaitre Vascular shares are held by institutional investors. 1.3% of MiMedx Group shares are held by company insiders. Comparatively, 10.8% of LeMaitre Vascular shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
MiMedx Group has a net margin of 18.63% compared to MiMedx Group's net margin of 16.99%. LeMaitre Vascular's return on equity of 39.42% beat MiMedx Group's return on equity.
MiMedx Group currently has a consensus target price of $12.00, indicating a potential upside of 54.64%. LeMaitre Vascular has a consensus target price of $77.57, indicating a potential downside of 9.62%. Given LeMaitre Vascular's stronger consensus rating and higher possible upside, equities research analysts plainly believe MiMedx Group is more favorable than LeMaitre Vascular.
MiMedx Group has a beta of 1.99, indicating that its stock price is 99% more volatile than the S&P 500. Comparatively, LeMaitre Vascular has a beta of 0.89, indicating that its stock price is 11% less volatile than the S&P 500.
LeMaitre Vascular received 467 more outperform votes than MiMedx Group when rated by MarketBeat users. However, 79.17% of users gave MiMedx Group an outperform vote while only 70.83% of users gave LeMaitre Vascular an outperform vote.
MiMedx Group has higher revenue and earnings than LeMaitre Vascular. MiMedx Group is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.
In the previous week, LeMaitre Vascular had 2 more articles in the media than MiMedx Group. MarketBeat recorded 6 mentions for LeMaitre Vascular and 4 mentions for MiMedx Group. MiMedx Group's average media sentiment score of 0.74 beat LeMaitre Vascular's score of 0.38 indicating that LeMaitre Vascular is being referred to more favorably in the news media.
Summary
LeMaitre Vascular beats MiMedx Group on 10 of the 19 factors compared between the two stocks.
Get LeMaitre Vascular News Delivered to You Automatically
Sign up to receive the latest news and ratings for LMAT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LMAT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
LeMaitre Vascular Competitors List
Related Companies and Tools
